InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Satellos Bioscience Inc.

MSLE Clue Score33
Canada (Federal Level) Fiscal year ends December CIK 0001421642
$7.17 -4.27% Close, 12 Oct 2026
Alert on the numbers Alert on insider trades
Price $7.17 −2.58% Close, 12 Oct 2026

Closing prices at the end of each trading day, from 6 Feb 2026. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
Operating incomeNet income
Fiscal year 2024Operating income−20.4Net income−20.6EPS, diluted−2.16Fiscal year 2025Operating income−26.5Net income−24.9EPS, diluted−1.70
FY2024FY2025
Operating income −20.4 −26.5
Net income −20.6 −24.9
Growth
EPS, diluted −2.16 −1.70

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2024Operating cash flow−18.3Capital expenditure−0.0Free cash flow−18.3Fiscal year 2025Operating cash flow−23.6Capital expenditure−0.0Free cash flow−23.6
FY2024FY2025
Operating cash flow −18.3 −23.6
Capital expenditure −0.0 −0.0
Free cash flow −18.3 −23.6
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash and securities
Fiscal year 2024Cash and securities40.1Shareholders’ equity47.2Fiscal year 2025Cash and securities9.8Shareholders’ equity27.8
FY2024FY2025
Cash and securities 40.1 9.8
Shareholders’ equity 47.2 27.8

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Balance sheet

In millions of USD, except per-share figures; shares in millions. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2024 31 Dec 2024 FY2025 31 Dec 2025
Assets
40.1 9.8
0.0 0.0
50.7 31.9
Growth −37.2%
Liabilities
3.6 4.1
Equity
−57.1 −82.0
47.2 27.8
Growth −41.1%
Per share and net cash
n/a 15.5
calc n/a 1.80

Lines marked calc are worked out here from filed figures; point at one for how.